You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Patent: 10,159,675


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,159,675
Title:Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
Abstract: Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.
Inventor(s): Hagner; Patrick (Sparta, NJ), Gandhi; Anita (Bernardsville, NJ), Pourdehnad; Michael (San Francisco, CA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:15/367,117
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,159,675

Introduction

Patents are a crucial component of innovation, protecting intellectual property and encouraging further research and development. The United States Patent 10,159,675, while not specifically detailed in the provided sources, can be analyzed within the broader context of patent claims and the patent landscape. Here, we will delve into the key aspects of patent claims, the evolving patent landscape, and the implications for inventors, businesses, and the legal community.

Understanding Patent Claims

Patent claims are the heart of any patent application, defining the scope of the invention and what is protected under the patent. The complexity and number of claims have been increasing over the years, with some applications including hundreds or even thousands of claims[2].

The Growing Complexity of Patent Claims

The rise in the number of patent applications and claims is driven by technological advancements and the need for comprehensive protection. For instance, the case of Festo Corporation v. Shoketsu Kinzoku Kogyo Kabushiki Co. Ltd. has led to a practice where inventors make narrowing amendments to claims to overcome examiner objections, which can significantly limit the scope of the patent claims[2].

Tools for Managing Patent Claims

To manage the increasing complexity, tools like the Patent Matrix software have been developed. This software automates the import of patent claims, parses them into a hierarchical order, and allows for compression and expansion of claims for easier review[2].

The Evolving Patent Landscape

Increase in Patent Applications

The number of patent applications has seen a significant rise over the years. From approximately 100,000 applications per year in the 1960s and 1970s to over 326,000 in 2001, the trend continues to grow, driven by technological innovation and facilitated by advancements in technology such as word processing and electronic database searching[2].

Role of AI in Patent Applications

The use of Artificial Intelligence (AI) in patent applications is becoming more prevalent. The USPTO has issued guidance on the use of AI tools, emphasizing the need to disclose any material contributions made by AI systems to the invention. This includes ensuring that AI-generated content does not introduce inaccurate statements or omit material information[3].

Patent Assertion Entities (PAEs)

PAEs, also known as patent trolls, play a significant role in the patent landscape. They can be categorized into Portfolio PAEs and Litigation PAEs. Portfolio PAEs negotiate licenses for large portfolios of patents, often without litigation, while Litigation PAEs frequently precede licensing with patent infringement suits. PAEs primarily focus on Information and Communication Technology (ICT) and software patents, asserting them against a wide range of industries[4].

Quality and Compliance in Patent Examinations

The USPTO has been working to improve the quality and consistency of patent examinations. Recommendations from the GAO have led to the development of correctness measures and compliance targets. These measures include statutory compliance rates for various sections of the patent code and have resulted in increased examination time for certain technology areas to ensure thorough reviews[5].

Impact on Inventors and Businesses

Protecting Intellectual Property

For inventors and businesses, understanding the patent landscape is crucial for protecting their intellectual property. The increasing complexity of patent claims and the role of AI in patent applications require careful navigation to ensure that all contributions, whether by humans or AI, are properly disclosed and credited[3].

Mitigating Risks

Practitioners must be aware of the risks associated with using AI tools in patent applications. Ensuring the accuracy of factual assertions and avoiding the submission of AI-generated evidence that does not reflect real-world use is essential to maintaining the integrity of the patent process[3].

Legal and Regulatory Considerations

Disclosure Requirements

The USPTO's guidance on AI tools highlights the importance of disclosing any material contributions made by AI systems. Failure to do so can lead to issues with patent validity and enforceability[3].

Litigation and Licensing

The behavior of PAEs, particularly Litigation PAEs, underscores the need for robust legal strategies. Businesses must be prepared to defend against patent infringement suits and negotiate licenses effectively to avoid costly litigation[4].

Key Takeaways

  • Complexity of Patent Claims: The number and complexity of patent claims are increasing, necessitating advanced tools for management.
  • Role of AI: AI is increasingly used in patent applications, but its contributions must be disclosed to the USPTO.
  • PAEs: Patent Assertion Entities play a significant role in the patent landscape, with different models of operation that can impact businesses.
  • Quality and Compliance: The USPTO is enhancing the quality and consistency of patent examinations through new measures and targets.
  • Legal Considerations: Proper disclosure and accuracy in patent applications, especially when using AI, are critical for maintaining patent validity.

FAQs

Q: What is the significance of patent claims in a patent application? A: Patent claims define the scope of the invention and what is protected under the patent, making them the most critical part of the application.

Q: How has the use of AI impacted the patent application process? A: AI tools can assist in drafting and analyzing patent applications, but any material contributions made by AI must be disclosed to the USPTO to ensure compliance.

Q: What are the different types of Patent Assertion Entities (PAEs)? A: PAEs can be categorized into Portfolio PAEs, which negotiate licenses without litigation, and Litigation PAEs, which often precede licensing with patent infringement suits.

Q: Why is it important to ensure the quality of patent examinations? A: Ensuring the quality of patent examinations helps maintain the integrity of the patent system by ensuring that patents are granted only for valid and novel inventions.

Q: What are the potential risks of using AI tools in patent applications? A: The potential risks include introducing inaccurate statements or omitting material information, which can affect the validity and enforceability of the patent.

Sources

  1. Department of Energy, "hfto-2021-patent-analysis.pdf"
  2. Google Patents, "US20110138338A1 - Patent Claims Analysis System and Method"
  3. Buchanan Ingersoll & Rooney PC, "U.S. Patent Office Issues Additional Guidance on Use of AI Tools"
  4. Federal Trade Commission, "Patent Assertion Entity Activity: An FTC Study"
  5. Government Accountability Office, "Intellectual Property: Patent Office Should Define Quality, Reassess ..."[5]

More… ↓

⤷  Subscribe

Details for Patent 10,159,675

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 10,159,675 2035-12-02
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 10,159,675 2035-12-02
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b Injection 103132 10,159,675 2035-12-02
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,159,675 2035-12-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.